Kornimate/medical-research-clean huggingface dataset:
development of machine learning models for the prediction of bmi and complications after bariatric surgery (cabs-study)

Conditions: Body Weight; Post-Op Complication; Anastomosis, Leaking; Hiatal Hernia; GERD; Internal Hernia; Mesenteric Hernia; Intussusception; Diabetes Mellitus, Type 2; Sleep Apnea, Obstructive

Summary: this study aims to develop machine learning models with the ability to predict patients' bmi and complications after bariatric surgery (cabs-score). this study also aims to develop machine learning models with the ability to predict diabetic (dm ii)patients' remission rate after bariatric surgery. the service mentioned above will be publicly available as a web-based application


Eligibility criteria:
inclusion criteria: * patients undergoing bariatric surgery * patients \>18 years exclusion criteria: * patients \<18 years * patients who cannot be followed up on for more than 6 month after surgery * patients who are unable to provide informed approval to participate according to each centre's rules will be excluded.

Keywords: bariatric surgery machine learning clinical prediction modelling artificial intelligence
b-type chronic lymphocytic leukemia (b-cll) subgroups: maturation stage and gene expression

Conditions: Chronic Lymphocytic Leukemia

Summary: b type chronic lymphocytic leukemia (b-cll) is the most prevalent leukemia in the western world. it is a disease that occurs primarily in aging individuals and occurs more frequently in males than females. although b-cll was considered a homogeneous condition, recent studies by our laboratory and others suggest that b-cll cases can be divided into two subgroups. these sub-groups can be identified by either the presence or the absence of mutations in antibody genes and/or by the percentage of b-cll cells expressing a particular protein called cd38. these two sub-groups (unmutated antibody genes high percent cd38 and mutated antibody genes low percentage cd38) follow strikingly clinically different courses. for example, the unmutated/cd38+ group experiences a much more aggressive disease and these patients almost invariably die much sooner than the cases in the other group. in addition, the patients in the mutated cd38+ group require much more chemotherapy than mutatedlcd38-. finally, surprisingly there is a much higher representation of males in the poor outcome unmutated cd38 group than in the better outcome group. the reasons for these differences in clinical outcome and gender bias are unknown.


Eligibility criteria:
inclusion criteria: * 18 years of age, * patients must be able to contribute the required amount of blood without compromising their well being, * participants must be willing to be contacted again in the future for additional blood drawing. exclusion criteria: * patients who are known to be anemic, with a hemoglobin \< 8, * patients who are known to be infected with hiv.

Keywords: chronic lymphocytic leukemia
quality of life and nutritional improvements in cirrhotic patients

Conditions: Liver Cirrhosis; Hepatic Encephalopathy; Portal Hypertension

Summary: the purpose of this study is to determine whether taking rifaximin (xifaxan) in conjunction with the use of nutritional concepts is effective in improving morbidity and quality of life in cirrhotic patients suffering from hepatic encephalopathy (he).

prevention of portal hypertension complications should be at the forefront. in doing so, the end result will be an improvement in the multitude of morbidity and mortality issues. the proposed prospective trial will compare patients with similar demographics and medical and clinical settings utilizing standard of care therapy. study subjects will be randomly assigned into two treatment groups. group one will receive lactulose 30ml three times a day as soc and rifaximin placebo 550mg twice a day with nutritional supervision and group two will receive rifaximin 550mg twice per day as soc and lactulose placebo 30ml three times per day with nutritional supervision.

Eligibility criteria:
inclusion criteria: * male and female gender of age 18 years or older * liver cirrhosis defined as one or more of the following: radio-graphically proven portal hypertension (ct with nodular appearance) or liver biopsy with cirrhosis * model for end stage liver disease (meld) score \< 20 * willingness to provide written informed consent, and participate in all study requirements * sodium greater than 130 meq/l * conn score \< 2 exclusion criteria: * active alcohol consumption * serum total bilirubin level \> 5 mg/dl * history of hepatocellular carcinoma (hcc) and malignancies other than basal cell carcinoma of the skin * pregnant or breastfeeding women * subject has renal insufficiency requiring routine dialysis * poorly controlled diabetes as defined by hga1c \> 10 * narcotic/psychotropic usage other than a stable dose of antidepressant and/or methadone. neurontin (gabapentin) and lyrica (pregabalin) are permitted if the subject has been on a stable dose for at least 2 months prior to the screening visit and no change of dosing is expected throughout the length of the trial * any of the following diagnoses: * hiv * evidence of severe concomitant illness or any condition that makes them unsuitable for the study in the opinion of the investigator(s) * subject has received an investigational drug within 30 days prior to enrollment
first-day computed tomography: does it has a role in the assessment of patients with inhalation lung injury?

Conditions: Inhalation Injury

Summary: a major risk factor for death in burn victims is inhalation lung injury. diagnostic criteria and severity grading are not well understood. after an inhalation injury, the mucociliary escalator is impaired by induced mucosal hyperemia, which includes edema, increased mucous production, and airway exudation, and these insults worsen airway narrowing which interferes with ventilation. multimodal therapy and quick bronchoscopic diagnosis improve patient outcomes. early identification and classification of inhalation injuries improve patient outcomes. chest ct may be employed as an alternative to or supplement to the bronchoscopy as well as a diagnostic and prognostic tool. in this study, the diagnostic and prognostic value of bronchial wall thickening as a radiological ct finding in inhalation lung damage and the radiologist score (rads) were evaluated.

forty-eight patients with inhalation lung injury were included in the study as the case group, and ten patients without ili were chosen as the control group. both groups were recruited from the burn and plastic department. a fiberoptic bronchoscope was performed during the first 12 hours of a suspected ili to confirm the diagnosis. after performing an initial chest x-ray, computed tomography was used to calculate the radiologist score (rads) and the thickness of the bronchial walls (bwt).

Eligibility criteria:
inclusion criteria: * any patient with a suspected inhalational lung injury exclusion criteria: * less than 18 years old, * patients who had their ct scan after 24 hours after their admission * patients who couldn't finish all of the study steps. * patients that are known to have any parenchymal lung disorders.

Keywords: inhalation injury bronchial wall thickening radiologist score computed tomography.
an open-label study on the clinical efficacy of tdcs intervention in pd

Conditions: Transcranial Direct Current Stimulation; Parkinson Disease; Primary Left Motor Cortex

Summary: to demonstrate that intervention targeting the primary motor area (m1) using transcranial direct current stimulation can improve sleep symptoms in patients with parkinson's disease.

rapid eye movement sleep behavior disorder (rbd) is one of the most common accompanying symptoms of parkinson's disease (pd). pd-rbd patients have more severe clinical manifestations, require larger drug doses, and have more non-motor symptoms. although several strategies using transcranial direct current stimulation (tdcs) have been investigated for the treatment of sleep disorders, the efficacy of high-definition tdcs (hd-tdcs) in pd-rbd patients remains unclear. we conducted an open-label study using the rbd-sq to identify individuals with possible rbd (prbd), and recruiting the patients at the first affiliated hospital of anhui medical university to receive cathodal hd-tdcs intervention. on the basis of conventional anti-pd drugs, cathodal hd-tdcs treatment was performed on the left m1 area once a day for 20 minutes, and the treatment was continued for 10 days. the international movement disorders society sponsored revision of the unified parkinson's disease rating scale (mds-updrs), the hoehn \& yahr staging scale (h\&y), rem sleep behavior disorder screening questionnaire (rbdsq), rbd screening questionnaire hong kong (rbdsq- hk), pittsburgh sleep quality index (psqi), epworth sleepiness scale (ess), and parkinson disease sleep scale (pdss) were assessed on intervention day 1 and day 10, and clinical efficacy was evaluated by comparing the scale scores before and after the intervention.

Eligibility criteria:
inclusion criteria: 1. the diagnosis of pd was determined by neurologists with rich clinical work experience, and was in line with the diagnostic criteria for parkinson's disease in china (2016 edition). 2. the total score of rbd screening questionnaire (rbdsq) is ≥6 points. 3. all patients took the drug stably and had no history of drug adjustment within 2 months before treatment. the test was conducted 2 hours after taking the drug. 4. good compatibility, with a certain degree of compliance; 5. normal mental condition, able to cooperate with behavioral tests and transcranial electrical stimulation treatment; exclusion criteria: 1. the patient has a metal object or skull brace device or any similar metal object on the scalp; 2. head tremor or limb shaking is so severe that it is difficult to calmly receive treatment; 3. the presence of other serious mental illness (such as major depression, psychosis or obsessive-compulsive disorder, physical illness or a history of substance abuse); 4. have a head injury, stroke or other neurological disorder; 5. the diagnosis of pd dementia is difficult to complete the assessment.

Keywords: transcranial direct current stimulation parkinson disease primary left motor cortex
the promise survey

Conditions: Prolactinoma; Pituitary Tumor

Summary: the promise survey was developed to systematically assess the real-world experiences, treatment preferences, side effects, and outcomes from both patients and physicians dealing with prolactinomas. the aim is to generate insights that can guide future clinical research and improve individualized care strategies.

background prolactinomas are the most common hormone-producing pituitary tumors, causing symptoms like menstrual irregularities, infertility, galactorrhea, and reduced libido due to elevated prolactin levels. the standard treatment involves dopamine agonists (das) such as cabergoline or bromocriptine, which are usually effective. however, many patients report side effects (e.g., nausea, dizziness, psychiatric symptoms), leading to challenges in long-term adherence and uncertainty about outcomes after discontinuing therapy. surgical treatment has emerged as a potentially safe and effective alternative, especially for selected patients, but perspectives from both patients and physicians on treatment preferences and outcomes are not well studied. the survey is designed to be completed in 5-10 minutes, fostering high participation across diverse patient and physician populations. data are collected anonymous covers the following areas: 1. patient characteristics 2. da therapy 3. surgical treatment 4. diagnostic pathway 5. treatment side effects \& recurrence 6. quality of life and psychosocial impact 7. physician perspectives 8. knowledge gaps 9. hypothesis generation outcome the collected data will inform: * better understanding of real-world management and challenges in prolactinoma care. * insights for improving clinical guidelines, patient education, and treatment decision-making. * hypotheses for future studies comparing outcomes of da therapy vs. surgery and optimizing long-term management strategies.

Eligibility criteria:
inclusion criteria: * prolactinoma patients * prolactinoma treating physicians including endocrinologists and neurosurgeons

Keywords: survey
continued safety evaluation of fb-401 in children, adolescents and adults (2 years and older) with mild to moderate atopic dermatitis previously enrolled in the fb401-01 study

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to evaluate the continued safety and tolerability of fb-401 in subjects 2 years of age or older with mild to moderate atopic dermatitis. fb-401 will be applied topically for up to 48 additional weeks and subjects will be evaluated for safety.


Eligibility criteria:
inclusion criteria: * participated in protocol fb401-01, completed through week 20 visit and able to directly enroll into this (fb401-02) study * refrain from use of all other atopic dermatitis treatments, unless given permission by medical monitor exclusion criteria: * subject experienced a serious adverse event or severe adverse event attributable to study drug in protocol fb401-01 * severe concomitant illness that, in the investigator's opinion, would adversely affect subject participation in the study, whether medical or psychological * pregnant (or planning to become pregnant during the period of the study) or lactating females

Keywords: atopic dermatitis microbiome probiotic commensal gram-negative bacteria transdermal water loss allergic diseases dermatitis eczema skin diseases skin diseases, eczematous immune system diseases
valproic acid in ambulant adults with spinal muscular atrophy

Conditions: Spinal Muscular Atrophy

Summary: the primary objective of this proposal is to determine whether oral vpa is effective in treating sma in adult patients.

participation in this study entails six visits and seven to eight blood draws over 13 months. each visit entails a stay of two days and one night at the general clinical research center (gcrc). subjects who live within driving distance will be allowed to participate in the study without an overnight stay through two consecutive outpatient visits. all subjects will be evaluated at two screening visits 2-4 weeks apart to determine eligibility for participation. eligible subjects will be randomized to receive vpa or placebo for the first six months. at the six-month visit, patients will be evaluated and crossed over to the other regimen.

Eligibility criteria:
inclusion criteria: 1. ambulatory adults with sma 3 ages 18-60. the diagnosis of sma must be documented by the homozygous deletion of both smn1 genes on standard genetic tests for the disorder. patients must be able to walk thirty feet without assistance (i.e. no canes, walkers). 2. interest in participating and the ability to meet the study requirements. 3. women of child bearing age are required to be on birth control or abstain while participating in the study. exclusion criteria: 1. non-ambulatory type 3 adults and all type 2 adults. 2. patients with co-morbid conditions that preclude travel, testing or study medications. 3. patients who have participated in a treatment trial for sma in the 3 months prior to this trial, or plan on enrolling in any other treatment trial during the duration of this trial. 4. patients who are, in the investigator's opinion, mentally or legally incapacitated from providing informed consent for the study, or are otherwise unable to meet study requirements or cooperate reliably with study procedures, especially strength testing. 5. patients with a need for non-invasive ventilatory support (e.g. bipap) for \> 12 hours/day 6. transaminases, amylase or lipase \> 3.0 x normal values, wbc \< 3.0 or neutropenia \< 1.0, platelet count \< 100 k, or hematocrit \< 30 persisting over a 30 day period 7. use of medications or supplements which interfere with vpa metabolism and increase the potential risks of the medications, or are hypothesized to have a beneficial effect in sma animal models or human neuromuscular disorders within 3 months of study enrollment. these agents include riluzole, creatine, butyrate derivatives, growth hormone, anabolic steroids, daily albuterol use, anticonvulsants, or other hdac inhibitors. 8. women who are pregnant or who intend to become pregnant while participating in the research study or who are breastfeeding.

Keywords: spinal muscular atrophy adult
optimizing low vision rehabilitation in emotionally distressed patients with inherited retinal diseases

Conditions: Inherited Retinal Diseases

Summary: the purpose of this study is to understand if combining low vision rehabilitation (lvr) with emotional regulation therapy (ert) can help people with inherited retinal diseases (irds) that experience emotional distress related to participants' vision loss. the study team hypothesize that treatment with lvr will produce measurable functional gains and that these effects will be enhanced by ert-linked improvement among the subgroup of ird patients with elevated vision-related anxiety.


Eligibility criteria:
inclusion criteria: * diagnosed with vision impairment with ird etiology * must have had a clinical exam with an ird specialist within the three months of assignment to arm * have had a goldmann visual field that was tested with iii-4e isopter within the last year * have a disability greater than zero theta in any of the domains of michigan retinal dystrophy questionnaire (mrdq) * have an indication from the ird specialist that the ocular condition will not deteriorate over the next 1- year * able to participate in 10 weeks of ert sessions while being physically located in michigan (these will take place in the first 10 months of the study) exclusion criteria: * having other ocular comorbidities including those associated with an ird such as control of cystoid macular edema (cme) * functional needs regarding low vision (i.e. activities of daily living) have been adequately addressed per a study low vision specialist * current mental health therapy * the participant must not have an elevated suicidal intention (si) or suicide risk based on patient health questionnaire (phq-9) further information collected at screening (if suicidal intentions are identified, the study staff will complete the suicide protocol (per protocol) * if the participant is using medication for mental health or psychiatry concerns, participants must be on a stable dose of the medication (1-month of taking), otherwise will be excluded * inability to complete study task requirements

Keywords: low vision rehabilitation emotional regulation therapy vision-related anxiety
early hydrogen-oxygen gas mixture inhalation in patients with aneurysmal subarachnoid hemorrhage (homa)

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: this was a randomized, single-center trial. on the basis of standard-of-care, patients in the treatment group inhaled h2-o2 (66% hydrogen; 33% oxygen) at 3 l/min via nasal cannula by using the hydrogen/oxygen generator (model ams-h-03, shanghai asclepius meditech co., ltd., china) during a 7-day stay in the intensive care unit. patients in the control group received standard-of-care (consisting of oxygen therapy) alone. this study intends to apply hydrogen/oxygen generator in clinical patients with aneurysmal subarachnoid hemorrhage (asah), exploring the role of hydrogen-oxygen mixed gas inhalation therapy in early brain injury, and the prevention of cerebral vasospasm and delayed cerebral ischemia, finally providing a scientific basis for hydrogen treatment of asah.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. signed informed consent 3. must be admitted within 72 hours after aneurysm rupture exclusion criteria: 1. physical disability caused by any reason before the onset of the disease 2. dementia or mental illness before the onset of the disease 3. more than 72 hours after aneurysm rupture admitted to hospital for treatment 4. do not cooperate with the treatment
efficacy and safety of the hcoil deep tms for the treatment of cannabis addiction

Conditions: Marijuana Abuse

Summary: evaluation of efficacy and safety of h-coil deep transcranial magnetic stimulation 9 week treatment trial for cannabis addiction as assessed by measures of drug intake and craving.


Eligibility criteria:
inclusion criteria: * male and female, aged 21-70 years, who meet dsm-iv tr diagnostic criteria for cannabis abuse and are motivated to quit cannabis use as assessed in the screening visit and gave their written informed consent to participate in the study. exclusion criteria: * history of a primary major psychiatric other then cannabis abuse, or cognitive disorder according to dsm-iv tr criteria. * hamilton depression scale rated 25 and above (moderate to severe depression) * current alcohol or other substance abuse or dependence * alcohol or other substance abuse or dependence during the last 12 months before recruitment. * history of or evidence of significant brain malformation,neoplasm, head injury, cerebral vascular events,neurodegenerative disorder or brain surgery. * severe somatic co-morbidity * history of seizures cardiac pace maker or other electronic implants pregnancy and lactation

Keywords: cannabis addiction craving tms
intratracheal suctioning and oxygenation at extubation

Conditions: Extubation

Summary: data analysis of routinely applied extubation procedures on the icu: i.e. extubation with 100% o2 vs. 35% o2 with/without suctioning.


Eligibility criteria:
inclusion criteria: * all adult (≥18 years) icu patients with routine extubation on the icu during the 2-month observational interval. exclusion criteria: * age \< 18 years * patients on comfort therapy and/ or terminal extubation or accidental extubationtracheostomized patients * patients with refusal to general consent or withdrawal of general consent (dlf and/or internal database) * patients dying without next-of-kin available

Keywords: critical illness icu extubation respiratory failure
analgesic effect of supraclavicular block and interscalene analgesia versus an intercostobrachial nerve block versus pca in forearm surgery

Conditions: Forearm Surgery; US-Guided Supraclavicular Block; Interscalene Analgesia; Tourniquet Pain

Summary: the etiology of tourniquet pain is complex, and the study team hypothesizes that blocking with interscalene brachial plexus block (isbpb) is more efficient in decreasing the incidence of tourniquet pain in comparison with other techniques. as there is a paucity of studies that evaluate the effect of intercostobrachial nerve (icbn) block and isbpb and patient-controlled analgesia (pca) with a supraclavicular brachial plexus block (scbpb) on tourniquet pain in forearm surgery, therefore, we established this randomized study to compare isbpb and icbn and pca with fentanyl with scbpb in terms of the incidence and severity of tourniquet pain in patients undergoing forearm surgery.


Eligibility criteria:
inclusion criteria: * aged more than 18 years, * asai-iii patients * scheduled to undergo orthopedic or plastic surgery distal to the elbow with an anticipated tourniquet duration greater than 45 min. * desiring regional anesthesia as the primary anesthetic. exclusion criteria: * contraindication to regional anesthesia. * allergy to local anesthetics. * primary block failure. * if patients desired deep intraoperative sedation. * clinically significant cognitive impairment.

Keywords: intercostobrachial nerve block pca with fentanyl